摘要
目的 核糖体蛋白L5(Ribosomal protein L5,RPL5)是核糖体蛋白家族成员.然而,RPL5在肿瘤发生、进展和免疫治疗中的作用尚未完全阐明.方法 通过多种数据库分析RPL5在泛癌中的表达,及其与肿瘤患者的预后、免疫细胞浸润、免疫调节基因、肿瘤突变负荷(tumor mutational burden,TMB)及微卫星不稳定性(microsatellite instability,MSI)的相关性.结果 与正常组织相比,RPL5在结肠癌、多形性胶质细胞瘤、肾透明细胞癌、肺腺癌、肺鳞癌、肝细胞肝癌中mRNA表达和蛋白质水平均升高,且RPL5是肾上腺皮质癌、肾乳头状细胞癌和肝细胞肝癌的预后危险因素.在某些癌症中,RPL5 表达与免疫细胞浸润、免疫调节基因、TMB及MSI呈负相关.结论 RPL5可作为癌症的预后生物标志物和潜在的免疫治疗靶点.
Abstract
Objective Ribosomal protein L5(RPL5)is a member of the ribosomal protein(RP)family.However,the role of RPL5 in tumourigenesis,progression and immunotherapy has not been fully elucidated.Methods The expression of RPL5 in pan-cancer and its correlation with prognosis,immune cell invasion,immunomodulatory genes,tumor mutational burden(TMB)and microsatellite instability(MSI)in cancer patients were analyzed through multiple databases.Results Compared with normal tissues,RPL5 was upregulated in colon adenocarcinoma,glioblastoma multiforme,renal clear cell carcinoma,lung adenocarcinoma,lung squamous cell carcinoma,and hepatocellular carcinoma at both mRNA expression and protein levels.And RPL5 as a significant prognostic risk factor for adrenocortical carcinoma,renal papillary cell carcinoma,and hepatocellular carcinoma.Furthermore,in certain cancers,there was an inverse correlation between RPL5 expression and immune cell infiltration,immunomodulatory genes,TMB,and MSI.Conclusion RPL5 could serve as a prognostic biomarker and potential immunotherapy target of cancer.
NETL
NSTL
万方数据